拉莫特里金在双相情感障碍中的疗效:系统性审查和元分析
N Haenen1,2, A M Kamperman1,3, A Prodan4
1Department of Psychiatry, Erasmus University Medical Center, Rotterdam, the Netherlands.
Bipolar disorders
|May 16, 2024
概括
拉莫特里金有效地治疗双相情感障碍 (BD) 抑郁症作为附加疗法,并预防复发作为维持治疗. 有证据支持其用于管理BD症状并减少住院治疗.
科学领域:
- 精神病学和制药科学 精神病学和制药科学
- 临床神经科学 临床神经科学
背景情况:
- 双极性障碍 (BD) 是一种慢性精神健康状况,其特点是情绪波动.
- 对BD有效的治疗策略对于管理患者的结果和减少复发率至关重要.
研究的目的:
- 综合当前临床证据,对拉莫特里金在治疗双相情感障碍 (BD) 的疗效.
- 为管理BD患者的医疗保健专业人员提供最新的临床指导.
主要方法:
- 按照PRISMA指南进行系统的文献搜索.
- 包括随机对照试验 (RCT) 和队列研究,评估拉莫特林在BD中的疗效.
- 基于治疗阶段 (急性抑郁,急性躁狂/低躁狂,维持),对照组 (安慰剂,活性比较剂) 和治疗策略 (单疗法,补充) 的分层分析.
主要成果:
- 与安慰剂 (SMD -0.30) 相比,拉莫因作为附加治疗显示出显著的有效性,可以减少抑郁症状.
- 作为维持治疗,拉莫特里金与安慰剂相比显著降低了复发/复发率 (RR 0.84).
- 与其他治疗方法相比,拉莫因与减少住院率有关.
结论:
- 实质性的证据支持lamotrigine在双相情感障碍 (BD) 中的疗效.
- 拉莫因作为急性抑郁症发作的补充疗法是有效的.
- 拉莫特里金作为一种有效的维持治疗,可以预防BD复发和复发.
相关概念视频
Mania and Antimanic Drugs: Overview
174
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
174
Bipolar Disorder
67
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
67
Antidepressant Drugs: MAOIs and Other Agents
226
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
226
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
287
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
287
Electroconvulsive Therapy
36
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
36
Psychosis: Goals of Pharmacotherapy
123
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
123


